Page 255 - 2021_07-Haematologica-web

Letters to the Editor
2. Fletcher L, Nabrinsky E, Liu T, et al. Cell death pathways in lym- phoid malignancies. Curr Oncol Rep. 2020;22(1):10.
3. Currie KS, Kropf JE, Lee T, et al. Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase. J Med Chem. 2014;57(9):3856-3873.
4. Gobessi S, Laurenti L, Longo PG, et al. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia. 2009; 23(4):686-697.
5. Paiva C, Rowland TA, Sreekantham B, et al. SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia. Haematologica. 2017;1 02(11):1890-1900.
6. Sharman J, Hawkins M, Kolibaba K, et al. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015;1 25(15):2336-2343.
7. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagno- sis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guide- lines. Blood. 2008;111(12):5446-5456.
8. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambu- cil in patients with CLL and coexisting conditions. N Engl J Med. 2014; 370(12):1101-1110.
9. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-
Hodgkin lymphoma and chronic lymphocytic leukemia. Blood.
2010;115(13):2578-2585.
10.Awan FT, Thirman MJ, Patel-Donnelly D, et al. Entospletinib
monotherapy in patients with relapsed or refractory chronic lym- phocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study. Leuk Lymphoma. 2019;60(8):1972-1977.
11. Danilov AV, Herbaux C, Walter HS, et al. Phase Ib study of tirabru- tinib in combination with idelalisib or entospletinib in previously treated chronic lymphocytic leukemia. Clin Cancer Res. 2020;2 6(12):2810-2818.
12. Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treat- ment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018;93(7):921-930.
13. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013; 369(1):32-42.
14. Gordon MJ, Churnetski M, Alqahtani H, et al. Comorbidities pre- dict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. Cancer. 2018;124(15):3192-3200.
15.Danilov AV, Persky DO. Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical prac- tice for the treatment of haematological malignancies. Br J Haematol. 2021;193(1):15-25.
haematologica | 2021; 106(7)
2025